Fermer le menu

Promega to Develop Microsatellite Instability (MSI) Companion Diagnostic IVD Kit in collaboration with GSK.



Madison, WI USA. (October 3, 2023) Promega Corporation today announced it plans to develop and commercialize a microsatellite instability (MSI) companion diagnostic (CDx) IVD kit with GSK to identify adult cancer patients with MSI-H solid tumors who may be eligible for potential treatment with GSK’s Jemperli (dostarlimab-gxly). The collaboration agreement leverages the companies’ complementary strengths to expand personalized healthcare options to more patients using high quality diagnostic tools and treatments.


Lire le communiqué de presse 

Plus d'infos